MX2022011856A - Anticuerpos de proteina tirosina cinasa especifica de musculo humano (musk) terapeuticos. - Google Patents

Anticuerpos de proteina tirosina cinasa especifica de musculo humano (musk) terapeuticos.

Info

Publication number
MX2022011856A
MX2022011856A MX2022011856A MX2022011856A MX2022011856A MX 2022011856 A MX2022011856 A MX 2022011856A MX 2022011856 A MX2022011856 A MX 2022011856A MX 2022011856 A MX2022011856 A MX 2022011856A MX 2022011856 A MX2022011856 A MX 2022011856A
Authority
MX
Mexico
Prior art keywords
musk
therapeutic
antibodies
present
musk antibodies
Prior art date
Application number
MX2022011856A
Other languages
English (en)
Inventor
Christophe Blanchetot
Karen Silence
Steven J Burden
Shohei Koide
Akiko Koide
Nadia Leloup
Julien Oury
Roeland Vanhauwaert
Original Assignee
Univ New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York filed Critical Univ New York
Publication of MX2022011856A publication Critical patent/MX2022011856A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a moléculas basadas en anticuerpos, incluyendo anticuerpos de longitud completa, dominios de unión al antígeno de los mismos, y derivados de anticuerpos que son capaces de unirse a, y activar la proteína tirosina cinasa específica de músculo humano (MuSK). La presente invención describe además métodos para tratar condiciones neuromusculares usando los anticuerpos de MuSK mencionados anteriormente.
MX2022011856A 2020-04-17 2021-04-16 Anticuerpos de proteina tirosina cinasa especifica de musculo humano (musk) terapeuticos. MX2022011856A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063011986P 2020-04-17 2020-04-17
US202063038633P 2020-06-12 2020-06-12
US202063112375P 2020-11-11 2020-11-11
PCT/US2021/027801 WO2021212053A2 (en) 2020-04-17 2021-04-16 Therapeutic musk antibodies

Publications (1)

Publication Number Publication Date
MX2022011856A true MX2022011856A (es) 2023-02-23

Family

ID=75850676

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011856A MX2022011856A (es) 2020-04-17 2021-04-16 Anticuerpos de proteina tirosina cinasa especifica de musculo humano (musk) terapeuticos.

Country Status (12)

Country Link
US (2) US11492401B2 (es)
EP (1) EP4136115A2 (es)
JP (1) JP7772715B2 (es)
KR (1) KR20230028217A (es)
CN (1) CN115843268A (es)
AU (1) AU2021256049A1 (es)
BR (1) BR112022021065A2 (es)
CA (1) CA3175597A1 (es)
IL (1) IL297295A (es)
MX (1) MX2022011856A (es)
PH (1) PH12022552483A1 (es)
WO (1) WO2021212053A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240135675A (ko) * 2022-01-28 2024-09-11 아르제넥스 비브이 신경근육성 장애를 치료하는데 사용하기 위한 항-MuSK 항체
WO2023218099A1 (en) * 2022-05-13 2023-11-16 argenx BV In utero treatment of a fetus having genetic disease/neuromuscular disease
EP4713359A1 (en) * 2023-05-15 2026-03-25 argenx BV Antibodies for use in agrin-deficient disorders
WO2025129132A1 (en) * 2023-12-14 2025-06-19 Invenra Inc. Multispecific binding agents that target ctla4 and/or cd25 and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
US5814478A (en) 1995-12-15 1998-09-29 Regeneron Pharmaceuticals, Inc. Tyrosine kinase receptors and ligands
US6737249B1 (en) 1997-08-22 2004-05-18 Genentech, Inc. Agonist antibodies
US6624819B1 (en) 2000-05-01 2003-09-23 Broadcom Corporation Method and system for providing a flexible and efficient processor for use in a graphics processing system
IL166244A0 (en) 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
EP1411851B1 (en) 2001-08-03 2006-11-02 Tyco Healthcare Group LP Marker for use with a tissue marking apparatus
US6921538B2 (en) 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
EP2545079A2 (en) 2010-03-11 2013-01-16 Rinat Neuroscience Corporation ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
JP2011207769A (ja) 2010-03-29 2011-10-20 Arubion:Kk 化粧料及び皮膚外用剤
WO2013074636A1 (en) 2011-11-14 2013-05-23 New York University Muscle specific receptor kinase and modulation thereof
US9574015B2 (en) 2013-09-13 2017-02-21 New York University Methods for treating muscle specific receptor kinase (MuSK) myasthenia gravis with the Ig1 domain of MuSK

Also Published As

Publication number Publication date
CN115843268A (zh) 2023-03-24
AU2021256049A1 (en) 2022-11-03
JP2023522212A (ja) 2023-05-29
PH12022552483A1 (en) 2024-02-05
US20230151091A1 (en) 2023-05-18
US20220259304A1 (en) 2022-08-18
KR20230028217A (ko) 2023-02-28
US11492401B2 (en) 2022-11-08
CA3175597A1 (en) 2021-10-21
WO2021212053A2 (en) 2021-10-21
JP7772715B2 (ja) 2025-11-18
IL297295A (en) 2022-12-01
WO2021212053A8 (en) 2022-09-29
BR112022021065A2 (pt) 2023-02-23
WO2021212053A3 (en) 2021-11-18
EP4136115A2 (en) 2023-02-22

Similar Documents

Publication Publication Date Title
PH12022552483A1 (en) Therapeutic musk antibodies
MX2021006971A (es) Anticuerpos anti-muc16 x anti-cd28 biespecificos y usos de estos.
MX2020013804A (es) Anticuerpos anti-psma x anti-cd28 biespecíficos y usos de estos.
EA202191580A1 (ru) Биспецифичные антитела анти-cd28 x анти-cd22 и их применение
EA201990781A1 (ru) Анти-steap2 антитела, конъюгаты антитело-лекарственное средство и биспецифические антигенсвязывающие молекулы, которые связывают steap2 и cd3, и их применение
PH12021500031A1 (en) Anti-il2 receptor gamma antigen-binding proteins
MY207784A (en) Anti-cd73 antibodies
JOP20190187A1 (ar) مترافقات عقار جسم مضاد لـ ccr7
BRPI0821658B8 (pt) anticorpo monoclonal humano ou um fragmento de ligação ao antígeno do mesmo que se liga a hnkg2d e seus usos
MX2023002106A (es) Anticuerpos fgfr3 y metodos de uso.
SA523442921B1 (ar) جزيئات ربط علاجية
EA202091747A1 (ru) Составы антитела b7-h4
EA202092125A1 (ru) Антитела против рецептора фолата 1 и их применения
MY206214A (en) Monoclonal antibodies that bind specifically to human trbv9
ZA202008095B (en) Humanized antibodies against psma
BR112022016232A2 (pt) Proteínas biespecíficas anti-her2 manipuladas
JOP20220255A1 (ar) أجسام tau المضادة لـ phf المضاد واستخداماتها
ZA202302392B (en) Antibodies against ilt2 and use thereof
MX2023004020A (es) Anticuerpos anti-ngf y métodos para su uso.
ZA202212133B (en) Anti-cd200r1 antibodies and methods of use thereof
ZA202208222B (en) Anti-acvr1 antibodies and uses thereof
ZA202110285B (en) Antibodies and methods of use
MX2022014224A (es) Construcciones de anticuerpos de dominio individual neutralizantes contra sars-cov2.
MX2025003153A (es) Anticuerpos anti-ccr8
MX2023013392A (es) Anticuerpos para tratar alfa-sinucleinopatias.